articleCancer CellJan 11, 2024HYBRID OA

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

DMDanish MemonAJAdam J. SchoenfeldDYDarwin YeGFGeorge FrommHRHira Rizvi

European Bioinformatics Institute · University of Cambridge · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows differential expression of inflammation and interferon (IFN) signaling. Relapsed tumors can be separated by upregulated or stable expression of IFNγ response genes. Upregulation of IFNγ response genes is associated with putative routes of resistance characterized by signatures of persistent IFN signaling, immune dysfunction, and mutations in antigen presentation genes which can be recapitulated in multiple…

Citation impact

175
total citations
FWCI
43.70
Percentile
100%
References
91
Citations per year

Authors

33

Topics & keywords

Topics
Keywords
  • Immunotherapy
  • Blockade
  • Downregulation and upregulation
  • Lung cancer
  • Cancer research
  • Immunology
  • Interferon
  • Immune system
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding